Type of ALL-B-lymphoblastic leukemia/lymphoma Posts on Medivizor
Navigation Menu

Type of ALL-B-lymphoblastic leukemia/lymphoma Posts on Medivizor

Evaluating the safety and effectiveness of blinatumomab for the treatment of children with relapsed or refractory B-cell acute lymphoblastic leukemia.

Evaluating the safety and effectiveness of blinatumomab for the treatment of children with relapsed or refractory B-cell acute lymphoblastic leukemia.

Posted by on Mar 20, 2022 in Leukemia | 0 comments

In a nutshell This study evaluated the safety and effectiveness of blinatumomab (Blincyto) for the treatment of children with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). The data showed that blinatumomab was safe and effective for these patients. Some background B-ALL is a type of cancer in which the body makes...

Read More

Evaluating therapies after CAR-T Cell treatment in patients with relapsed and refractory ALL

Evaluating therapies after CAR-T Cell treatment in patients with relapsed and refractory ALL

Posted by on Feb 6, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to investigate if allogeneic hematopoietic stem cell transplant (alloHSCT) was a suitable treatment strategy for patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) after chimeric antigen receptor (CAR) T-cell therapy.   This study concluded that this was a suitable treatment...

Read More

Restricting calories and nutrients to change chemotherapy effectiveness for acute lymphoblastic leukemia

Restricting calories and nutrients to change chemotherapy effectiveness for acute lymphoblastic leukemia

Posted by on May 23, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if restricting calories and nutrients from diet and exercise could change chemotherapy effectiveness in patients with B-cell acute lymphoblastic leukemia (ALL).  This study concluded that restricting calories/nutrients via diet and exercise changed chemotherapy effectiveness and...

Read More

Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Posted by on Apr 18, 2021 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of inotuzumab ozogamicin (Besponsa; INO) in patients with relapsed/refractory (r/r) acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The data showed that the treatment had good effectiveness and manageable side effects for these patients. Some background A high number...

Read More

Inotuzumab ozogamicin in patients with hard to treat, Philadelphia chromosome-positive acute lymphoblastic leukemia

Inotuzumab ozogamicin in patients with hard to treat, Philadelphia chromosome-positive acute lymphoblastic leukemia

Posted by on Dec 26, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of inotuzumab ozogamicin (InO; Besponsa) in patients with Philadelphia chromosome-positive (Ph+) relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL). This study concluded that this treatment is a good option for these patients.  Some background Ph chromosome...

Read More

Blinatumomab or inotuzumab ozogamicin as a bridge to stem cell transplant in relapsed/refractory B-cell acute lymphoblastic leukemia

Blinatumomab or inotuzumab ozogamicin as a bridge to stem cell transplant in relapsed/refractory B-cell acute lymphoblastic leukemia

Posted by on Oct 30, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the use of blinatumomab Blincyto; B) or inotuzumab ozogamicin (Besponsa; IO) as a bridge to stem cell transplant for patients with relapsed or refractory (unresponsive) B-cell acute lymphocytic leukemia (B-ALL).  This study concluded that both treatments are safe and effective as a...

Read More

The effects of blinatumomab in patients with relapsed or unresponsive acute lymphoblastic leukemia in outside of clinical trials

Posted by on Feb 24, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the safety and effectiveness of blinatumomab (Blincyto) in patients with relapsed or unresponsive B-acute lymphoblastic leukemia (B-ALL) outside of clinical trials. The authors found that blinatumomab was safe and effective to treat such patients in real-world medical practice. Some background Relapsed...

Read More

The effects of blinatumomab therapy in patients with relapsed/refractory acute lymphoblastic leukemia before transplantation

Posted by on Feb 19, 2020 in Leukemia | 0 comments

In a nutshell The study investigated whether blinatumomab (Blincyto) can be used for salvage therapy before hematopoietic cell transplantation (HCT) in patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). The main finding was that blinatumomab can be safely and effectively used in patients with r/r B-ALL before HCT. Some...

Read More

Minimal residual disease response leading to better outcomes for patients with relapsed/refractory acute lymphoblastic leukemia after treatment with blinatumomab

Minimal residual disease response leading to better outcomes for patients with relapsed/refractory acute lymphoblastic leukemia after treatment with blinatumomab

Posted by on Dec 7, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the relationship between minimal residual disease response and outcomes in patients with relapsed/unresponsive B-cell precursor acute lymphoblastic leukemia who were treated with blinatumomab.   This study concluded that achieving minimal residual disease response leads to better outcomes for...

Read More

Stem cell transplant after blinatumomab in patients with relapsed or unresponsive acute lymphoblastic leukemia

Stem cell transplant after blinatumomab in patients with relapsed or unresponsive acute lymphoblastic leukemia

Posted by on Sep 13, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes for patients who underwent allogeneic hematopoietic stem cell transplant after treatment with blinatumomab.  This study concluded that survival was driven by the response to study treatment and by salvage status regardless of transplant status.   Some...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor